Device Week, 25 March 2021 – Abernethy To Leave FDA; Dermal Fillers And Adverse Events
This week’s podcast tackles US FDA second-in-command Amy Abernethy’s surprise announcement that she’s leaving the agency. Then, we reveal how an FDA panel thinks dermal fillers like Restylane can be made safer for consumers following a recent uptick in serious adverse events.
Listen to the podcast via the player below:
Medtech Insight articles addressing topics discussed in this episode: